← back to search

Kurt Griffin

Royal Devon & Exeter NHS Foundation Trust · US
Area of research
Genetics · Surgery
Research interest
Research interests include Diabetes and associated disorders, Pancreatic function and diabetes, Diabetes Management and Research, and Phosphodiesterase function and regulation.
h-index
30
citations
3,364
works
90
NIH funding
primary concept
Medicine
email

Recent publications

Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes
Diabetes Care 2024cited by 63position: middledoi
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes
Science Translational Medicine 2024cited by 60position: middledoi
Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes
Diabetologia 2024cited by 55position: middledoi
Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review
Communications Medicine 2024cited by 43position: middledoi
Correction to: Consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes
Diabetologia 2024cited by 3position: middledoi
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review
Communications Medicine 2023cited by 26position: middledoi
Hydroxychloroquine in Stage 1 Type 1 Diabetes
Diabetes Care 2023cited by 16position: middledoi
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective
Diabetes 2022cited by 219position: middledoi
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
JCI Insight 2021cited by 58position: middledoi
A <i>Coccidioides posadasii CPS1</i> Deletion Mutant Is Avirulent and Protects Mice from Lethal Infection
Infection and Immunity 2016cited by 71position: middledoi
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial
The Lancet Diabetes & Endocrinology 2014cited by 91position: firstdoi
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
The Lancet Diabetes & Endocrinology 2013cited by 206position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Stephen S. Rich · Antwerp University Hospital1 papers (2022–2022)Anna E. Long · University of Bristol1 papers (2022–2022)Hema P. Narra · University of Arizona1 papers (2016–2016)Marc J. Orbach · University of Arizona1 papers (2016–2016)Michael Gottschalk · University of California San Diego1 papers (2014–2014)John N. Galgiani · University of Arizona1 papers (2016–2016) · 1 papers (2022–2022) · 1 papers (2014–2014)Mikael Knip · and Helsinki University Hospital1 papers (2022–2022)Andrea K. Steck · St Thomas' Hospital1 papers (2022–2022)Jeffrey A. Frelinger · University of Arizona1 papers (2016–2016)Cristy Geno Rasmussen · University of Colorado Health1 papers (2022–2022)Carla J. Greenbaum · Center for Infectious Disease Research1 papers (2022–2022)Colin Dayan · KU Leuven1 papers (2022–2022)Olga Kordonouri · Kinderkrankenhaus auf der Bult1 papers (2022–2022)Kevan C. Herold · Yale New Haven Hospital1 papers (2022–2022)Rachel Besser · Centre for Human Genetics1 papers (2022–2022)Emily K. Sims · University School1 papers (2022–2022)William Hagopian · Indiana University Health1 papers (2022–2022)Lisa F. Shubitz · University of Arizona1 papers (2016–2016)